These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Glaxo move seen as 'unavoidable'. Dickson D Nature; 1995 Mar; 374(6517):6. PubMed ID: 7870169 [No Abstract] [Full Text] [Related]
13. Glaxo to close top-ranked institute. Balter M Science; 1997 Oct; 278(5337):379. PubMed ID: 9381135 [No Abstract] [Full Text] [Related]
14. Canadian High Court upholds Glaxo Wellcome AZT patent. AIDS Policy Law; 2002 Dec; 17(22):3. PubMed ID: 12510642 [No Abstract] [Full Text] [Related]
15. UK biotechnology. Biotechnology no longer Wellcome. Aldhous P Nature; 1990 Oct; 347(6293):507. PubMed ID: 2215672 [No Abstract] [Full Text] [Related]
16. Genentech loses appeal against Wellcome. McGourty C Nature; 1988 Nov; 336(6194):4. PubMed ID: 3141815 [No Abstract] [Full Text] [Related]
17. Wellcome Trust to double spending after sale of shares. Mundell I Nature; 1992 Jul; 358(6385):359. PubMed ID: 1641012 [No Abstract] [Full Text] [Related]
18. [Glaxo Wellcome, Germany, spends 60.000 DM for African HIV projects in Uganda and Malawi]. Krankenpfl J; 1999 Dec; 37(12):479. PubMed ID: 10734858 [No Abstract] [Full Text] [Related]
19. Wellcome pledges $80 million for population studies. Nature; 1995 Mar; 374(6520):297. PubMed ID: 7885456 [No Abstract] [Full Text] [Related]
20. Glaxo goes back to basics in bid to meet new goals. Dickson D Nature; 1994 Feb; 367(6462):402. PubMed ID: 8107787 [No Abstract] [Full Text] [Related] [Next] [New Search]